Published in final edited form as:

Immunogenetics. 2012 June ; 64(6): 461–468. doi:10.1007/s00251-012-0600-x.

Identification of the peptide-binding motif recognized by the pigtail macaque class I MHC molecule Mane-A1*082:01 (Mane A*0301)

Carrie Moore,

La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA

John Sidney,

La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA

A. Michelle English,

Department of Chemistry, University of Virginia, Charlottesville, VA 22908, USA

Amanda Wriston,

Department of Chemistry, University of Virginia, Charlottesville, VA 22908, USA

Donald F. Hunt,

Department of Chemistry and Pathology, University of Virginia, Charlottesville, VA 22908, USA

Jeffrey Shabanowitz,

Department of Chemistry, University of Virginia, Charlottesville, VA 22908, USA

Scott Southwood,

La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA

Kate Bradley,

La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA

Bernard A. P. Lafont,

Non-Human Primate Immunogenetics and Cellular Immunology Unit, Laboratory of Molecular Microbiology, NIAID/NIH, Bethesda, MD 20892, USA

Bianca R. Mothé, and

Department of Biological Sciences, California State University–San Marcos, San Marcos, CA 92069, USA

Alessandro Sette

La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA

Alessandro Sette: alex@liai.org

Abstract

Rhesus and pigtail macaques have proven to be valuable animal models for several important human diseases, including HIV, where they exhibit similar pathology and disease progression. Because rhesus macaques have been extensively characterized in terms of their major histocompatibility complex (MHC) class I alleles, their demand has soared, making them increasingly difficult to obtain for research purposes. This problem has been exacerbated by a

continued export ban in place since 1978. Pigtail macaques represent a potential alternative animal model. However, because their MHC class I alleles have not been characterized in detail, their use has been hindered. To address this, in the present study, we have characterized the peptide binding specificity of the pigtail macaque class I allele Mane-A1*082:01 (formerly known as Mane A*0301), representative of the second most common MHC class I antigen detected across several cohorts. The motif was defined on the basis of binding studies utilizing purified MHC protein and panels of single amino acid substitution analog peptides, as well as sequences of peptide ligands eluted from Mane-A1*082:01. Based on these analyses, Mane-A1*082:01 was found to recognize a motif with H in position 2 and the aromatic residues F and Y, or the hydrophobic/aliphatic residue M, at the C-terminus. Finally, analysis of the binding of a combinatorial peptide library allowed the generation of a detailed quantitative motif that proved effective in the prediction of a set of high-affinity binders derived from chimeric SIV/HIV, an important model virus for studying HIV infection in humans.

Keywords

MHC; Macaques; Peptide binding motif; T cell epitope; Class I

The simian immunodeficiency virus (SIV) or chimeric SIV/ HIV (SHIV)-infected rhesus (*Macaca mulatta*) and pigtail (*Macaca nemistrina*) macaques are common animal models in the field of HIV/AIDS research. SIV and HIV type 1 are not only similar in genomic structure but also in the immunopathology they induce in their respective hosts (Liska et al. 1999). SIV and SHIV infection of macaques results in similar CD4+ T cell exhaustion and disease progression to immunodeficiency as found in HIV-1-infected humans (Balamurali et al. 2010; Boberg et al. 2008; Henning et al. 2011; Kearney et al. 2011; Klatt et al. 2011; Reece et al. 2010; Smith et al. 1999).

The control of both acute and chronic HIV and SIV infections has been linked to CD8+ T cell responses that are MHC class I restricted (De Rose et al. 2008; Hatziiannou et al. 2009; Loffredo et al. 2004; Mankowski et al. 2008; Miller et al. 1991; Smith et al. 2005). Rhesus macaques have been extensively characterized in terms of their major histocompatibility complex (MHC) class I alleles, and the detailed characterization of the peptide-binding specificity of several rhesus macaque MHC class I molecules (Mamu) has proven to be a useful tool to facilitate the identification of SIV epitopes recognized in infected animals (Allen et al. 2001; Allen et al. 1998; Hickman-Miller et al. 2005; Loffredo et al. 2009; Loffredo et al. 2005; Loffredo et al. 2004; Mothe et al. 2002; Peters et al. 2005; Sette et al. 2005; Sidney et al. 2000; Solomon et al. 2010; Southwood et al. 2011; Walsh et al. 2009). As a result, they have proven to represent very valuable animal models for use in HIV vaccine and pathogenesis studies, as well as for studies for several other human diseases such as influenza, hepatitis, and smallpox (Gardner and Luciw 2008). Unfortunately, because rhesus macaques are in high demand for such studies, they are becoming increasingly harder to obtain for research purposes—a situation exacerbated by the continued export ban placed on them in 1978 (Hatziiannou et al. 2009; Smith et al. 2005).

Pigtail macaques represent a potential alternative animal model to shoulder the research burden caused by the scarcity of available rhesus macaques. Despite the initial identification of their MHC class I alleles (Mane) (Lafont et al. 2003; Lafont et al. 2007; Smith et al. 2005), the characteristics of their peptide binding properties are largely unknown and, as a result, their use in similar types of studies has been hindered. With the eventual goal of creating vaccines for SIV and HIV, it is crucial that more is known about the cellular immune responses of this increasingly important animal model.

The pigtail macaque class I type Mane-A1*082:01, formerly known as Mane A*0301, is the second most common pigtail macaque MHC allele, with a frequency of approximately 23% across several cohorts (Pratt et al. 2006), making it an attractive target for characterization. The B pocket primary structure of Mane-A1*082:01 is very similar to that of the HLA class I allele B*2705, which has been associated with long-term disease non-progression in HIV-infected individuals (Carrington and O'Brien 2003), thus making Mane-A1*082:01 all the more interesting in the context of HIV vaccine development studies. Characterization of the peptide binding specificity of Mane-A1*082:01 would allow researchers to expand the usefulness of these animals in future HIV/SIV studies, as well as several other potential disease indications.

As an initial step to characterize the Mane-A1*082:01 binding specificity, we developed an in vitro MHC-peptide binding assay utilizing purified MHC molecules. The assay was developed utilizing published methodologies (Sidney et al. 2008a; Sidney et al. 2001), and Mane-A1*082:01 molecules were purified from a 721.221 cell line stably transfected with the allele (Allen et al. 1998; Loffredo et al. 2009; Shimizu and DeMars 1989). As the radiolabeled probe, an analog (peptide 3263.0005; sequence DHQAAFQYI) of the SHIV Gag-derived Mane-A1*082:01-restricted T cell epitope (Lafont et al., manuscript in preparation) was designed to incorporate a tyrosine residue (I8 to Y) to allow for radiolabeling and to replace the endogenous methionine (M6 to F) to increase stability. In direct binding assays with 3263.0005, a signal-to-noise ratio of about 5 could be detected with as little as 10 nM of purified MHC (data not shown). Inhibition assays to validate binding specificity and sensitivity revealed that the binding of 3263.0005 could be inhibited by unlabeled peptide in a dose-dependent manner, with an IC₅₀ of 8.2 nM.

Development of a sensitive binding assay allowed us to probe the specificity of Mane-A1*082:01 in detail. A panel of individual single amino acid substitution (SAAS) analogs, corresponding to substitution with each of the 20 naturally occurring amino acids at each position of peptide 3263.0005, was tested for its capacity to bind Mane-A1*082:01. To derive a detailed binding motif, the data were analyzed essentially as described previously (Sidney et al. 2008a). Briefly, the IC₅₀ (in nanomoles) values for each single substituted peptide were standardized as a ratio to the geometric IC₅₀ (in nanomoles) value of the entire panel of 172 analog peptides, and then normalized at each position so that the value associated with optimal binding at each position corresponds to 1. For each position, an average (geometric) relative binding affinity (ARB) was calculated. The ratio of the ARB values for each position to the entire SAAS panel is denominated as the specificity factor (SF). For SAAS panels, primary anchor positions are then defined as those with an SF ≥ 5 . This criterion identifies positions where the majority of residues are associated with significant decreases in binding capacity, signifying position-specific stringency. The binding data are summarized in Table 1.

As shown in Table 1, position 2 and the C-terminus were defined as the main anchor positions, with SF of 24 and 5.3, respectively. At position 2, histidine (H) was clearly the most dominant residue. Substitution with any other residue resulted in a 30-fold or more decrease in binding capacity, relative to the (wild-type) peptide with H in position 2, and in total 17 amino acids were associated with reductions greater than 50-fold. At the C-terminus, the aromatic residue phenylalanine (F) was the most preferred. The aromatic residue tyrosine (Y) was the second most preferred, with an ARB of 0.232, followed by M (ARB=0.158). A few other residues (R, L, C, and I) were tolerated at the C-terminus, with ARBs in the 0.02–0.1 range, but the remaining 13 amino acids were associated with 50-fold or greater reductions in binding capacity.

Secondary influences on peptide binding were most prominent in positions 5 and 7, where 7 and 10 substitutions, respectively, were associated with 50-fold or greater reductions in binding capacity, relative to the optimal residue. These positions, also associated with the next highest SFs (2.27 and 1.87, respectively), have been identified as secondary anchor positions for several HLA class I molecules (see, e.g., (Ruppert et al. 1993; Sidney et al. 2008a)). Influences at other positions were relatively minor.

The initial motif was defined on the basis of analogs of a single ligand. To verify that this motif was generally applicable to Mane-A1*082:01 ligands, and to determine the optimal ligand size for Mane-A1*082:01 molecules, we utilized previously described methodologies (Bairoch and Apweiler 2000; Geer et al. 2004; Udeshi et al. 2008) to elute, and then analyze by tandem mass spectrometry (MS/MS), ligands endogenously bound to purified Mane-A1*082:01 molecules. Data from the MS/MS experiments were searched against the SwissProt human database using the open mass spectrometry search algorithm (OMSSA) software to generate a list of candidate peptide sequences (ESM Table 1). Among the 46 peptides identified, 20 (43.5%) were nine residues in length. Longer peptides of 10 and 11 residues in length were also relatively common, being represented by 7 (15.2%) and 11 (23.9%) sequences, respectively. Only two 8-mer peptides (4.3%) were identified, suggesting that peptides shorter than nine residues are less well tolerated by Mane-A1*082:01. Similarly, while peptides longer than 11 residues were identified, these longer peptides collectively only represented less than 15% of all eluted ligands.

Next, the sequences of the eluted peptides were analyzed to determine the absolute number and relative fraction of occurrence for each individual amino acid, at each position (ESM Table 2 and Table 2, respectively). To do this, all of the peptides were aligned beginning at their N-terminus as shown in ESM Table 2, and the corresponding amino acid frequencies were determined for positions 1 through 8, and then for the C-terminal residue. Utilizing the fraction of occurrence data (Table 2), we defined main anchor positions as those where the median fraction of occurrence of any amino acid is 0, indicating that only a limited range of residues is found and implying that these positions are associated with the most severe specificity. Accordingly, and in agreement with the SAAS data, position 2 and the C-terminus were identified as main anchors, and at both of these positions there was a striking dominant preference for a single residue. More specifically, histidine was found at position 2 in 33 (72%) of the 46 sequenced peptides, and tyrosine was found at the C-terminus in 31 peptides (67%). At these positions, 14 and 15 different amino acids, respectively, were never seen in any of the eluted ligands. A dominant presence of asparagine (N) was also noted in position 1, although a number of other residues were also tolerated, suggesting that this is a secondary anchor position.

When compared to the SAAS data, the hierarchy of preferences at the C-terminus identified in the eluted peptides was a bit surprising. Specifically, the aromatic residue Y was clearly the most dominant residue among the eluted ligands, being present with about a fourfold higher frequency than F, whereas the SAAS analysis identified a fourfold higher preference for F. However, it should be noted that the SAAS data directly reflect molecular binding affinity, generated in vitro using purified reagents, whereas preferences determined on the basis of the elution data may be attenuated by factors inherent in the in vivo cellular environment, such as protein expression patterns, endogenous protein amino acid composition, and the preferences and/or limitations of protein processing mechanisms.

Finally, to develop a general prediction method for identifying candidate Mane-A1*082:01 epitopes, we determined the Mane-A1*082:01 binding capacity of a combinatorial peptide library (PSCL). Quantitative matrices developed using this approach have previously been shown effective for the prediction of peptide binders (Laumoller et al. 2001; Peters et al.

2006; Sidney et al. 2008a; Sidney et al. 2007; Stryhn et al. 1996; Udaka et al. 2000; Udaka et al. 1995). Accordingly, the PSCL data were analyzed as previously described, and a scoring matrix derived (Table 3) (Sidney et al. 2008a).

To evaluate the efficacy of the PSCL matrix for predicting Mane-A1*082:01 binders, we selected all possible 9-mer peptides derived from the SHIV DH12R clone 7 sequence (Sadjadpour et al. 2004). Similar to what was done previously for other MHC class I alleles (Loffredo et al. 2009; Sidney et al. 2008a; Sidney et al. 2007), each peptide was assigned a score representing the sum of the (log) matrix value for the corresponding residue at each position. The top 4% scoring peptides ($n = 124$) were then selected, synthesized, and tested for their capacity to bind Mane-A1*082:01 in competition assays utilizing purified MHC, as previously described (Loffredo et al. 2009; Sidney et al. 2008a; Sidney et al. 2001). A control set of over 200 peptides, selected to cover the 4–100% range, was also tested. As shown in Fig. 1a, the algorithm demonstrated specificity, with over 30% of the peptides scoring in the top 2 percentile range binding Mane-A1*082:01 with an affinity of 500 nM or better. By contrast, only 7.6% of the peptides in the second to tenth percentile range, and 3.4% in the 10th to 25th percentile range, were binders. None of the 72 peptides at the 25th or worse percentile bound Mane-A1*082:01. Figure 1b details the prediction efficacy of peptides scoring in the top 4%, demonstrating that effective saturation is achieved at about the second percentile (AUC=0.79). The PSCL matrix was also adapted to predict binders of 8, 10, and 11 residues in length. Synthesis and testing of the top 1% scoring peptides of each size demonstrated a similar prediction performance to that seen when predicting 9-mers, with between 23% and 35% of the peptides binding with an affinity of 500 nM or better. All peptides identified in the present study with Mane-A1*082:01 binding affinities of 500 nM, or better, represent candidates for T cell epitopes, and are listed in ESM Table 3.

In the context of most human and non-human primate MHC class I alleles studied to date, it has been shown that an appreciable fraction of high-affinity binders, and T cell epitopes, do not strictly adhere to canonical, elution-based, motifs (Kast et al. 1994; Kubo et al. 1994; Ruppert et al. 1993; Sette et al. 1994). The PSCL predictions demonstrate that this also appears to be true for Mane-A1*082:01. Specifically, while 53% (20/38) of the high-affinity peptides (IC₅₀ <100 nM) identified had H in position 2, and 76% (29/38) had F or Y at the C-terminus, only 29% conformed to the canonical motif at both main anchor positions (ESM Table 3). These observations underline the value of the detailed motif defined herein.

In the present study we have utilized MHC elution analyses and panels of single amino acid substitution analog peptides to probe the binding specificity of Mane-A1*082:01, one of the most frequent MHC class I alleles expressed in captive bred pigtail macaques. Based on these analyses, Mane-A1*082:01 was found to recognize a motif with a preference for H in position 2 and the aromatic residues F and Y, or the hydrophobic/aliphatic residue M, at the C-terminus. The development of a sensitive MHC-peptide binding assay utilizing purified MHC allowed the derivation of a detailed quantitative motif that was proven effective in predicting high-affinity binders from SHIV, an important model virus for studying HIV infection in humans. Future studies will address recognition of SHIV peptides in the context of Mane-A1*082:01 monkeys infected with SHIV, as well as potential binding cross-reactivity between Mane-A1*082:01 and Mamu A1*007:01, a rhesus macaque allele that recognizes a nearly identical primary anchor binding motif (Reed et al. 2011), and that has been associated with SIV elite controllers. Additional work will explore cross-reactivity with HLA alleles, such as those in the HLA B27 supertype (Sidney et al. 2008b), that recognize a similar peptide binding motif.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This study was supported in part by the Intramural Research program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH NIAID contract HHSN272200900042C (A.S.), and NIH grant AI33993 (DFH).

References

- Allen TM, Sidney J, del Guercio MF, Glickman RL, Lensmeyer GL, Wiebe DA, DeMars R, Pauza CD, Johnson RP, Sette A, Watkins DI. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. *J Immunol.* 1998; 160:6062–6071. [PubMed: 9637523]
- Allen TM, Mothe BR, Sidney J, Jing P, Dzuris JL, Liebl ME, Vogel TU, O'Connor DH, Wang X, Wussow MC, Thomson JA, Altman JD, Watkins DI, Sette A. CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing. *J Virol.* 2001; 75:738–749. [PubMed: 11134287]
- Bairoch A, Apweiler R. The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. *Nucleic Acids Res.* 2000; 28:45–48. [PubMed: 10592178]
- Balamurali M, Petravic J, Loh L, Alcantara S, Kent SJ, Davenport MP. Does cytolysis by CD8+ T cells drive immune escape in HIV infection? *J Immunol.* 2010; 185:5093–5101. [PubMed: 20881189]
- Boberg A, Brave A, Johansson S, Wahren B, Hinkula J, Rollman E. Murine models for HIV vaccination and challenge. *Expert Rev Vaccines.* 2008; 7:117–130. [PubMed: 18251698]
- Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. *Annu Rev Med.* 2003; 54:535–551. [PubMed: 12525683]
- De Rose R, Mason RD, Loh L, Peut V, Smith MZ, Fernandez CS, Alcantara S, Amarasena T, Reece J, Seddiki N, Kelleher AD, Zaunders J, Kent SJ. Safety, immunogenicity and efficacy of peptide-pulsed cellular immunotherapy in macaques. *J Med Primatol.* 2008; 37(Suppl 2):69–78. [PubMed: 19187433]
- Gardner MB, Luciw PA. Macaque models of human infectious disease. *ILAR J/Natl Res Counc, Inst Lab Anim Res.* 2008; 49:220–255.
- Geer LY, Markey SP, Kowalak JA, Wagner L, Xu M, Maynard DM, Yang X, Shi W, Bryant SH. Open mass spectrometry search algorithm. *J Proteome Res.* 2004; 3:958–964. [PubMed: 15473683]
- Hatzioannou T, Ambrose Z, Chung NP, Piatak M Jr, Yuan F, Trubey CM, Coalter V, Kiser R, Schneider D, Smedley J, Pung R, Gathuka M, Estes JD, Veazey RS, KewalRamani VN, Lifson JD, Bieniasz PD. A macaque model of HIV-1 infection. *Proc Natl Acad Sci USA.* 2009; 106:4425–4429. [PubMed: 19255423]
- Henning T, Fakile Y, Phillips C, Sweeney E, Mitchell J, Patton D, Sturdevant G, Caldwell HD, Secor WE, Papp J, Hendry RM, McNicholl J, Kersh E. Development of a pigtail macaque model of sexually transmitted infection/HIV coinfection using *Chlamydia trachomatis*, *Trichomonas vaginalis*, and SHIV (SF162P3). *J Med Primatol.* 2011; 40:214–223. [PubMed: 21781129]
- Hickman-Miller HD, Bardet W, Gilb A, Luis AD, Jackson KW, Watkins DI, Hildebrand WH. Rhesus macaque MHC class I molecules present HLA-B-like peptides. *J Immunol.* 2005; 175:367–375. [PubMed: 15972670]
- Kast WM, Brandt RM, Sidney J, Drijfhout JW, Kubo RT, Grey HM, Melief CJ, Sette A. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. *J Immunol.* 1994; 152:3904–3912. [PubMed: 7511661]
- Kearney M, Spindler J, Shao W, Maldarelli F, Palmer S, Hu SL, Lifson JD, KewalRamani VN, Mellors JW, Coffin JM, Ambrose Z. Genetic diversity of simian immunodeficiency virus encoding

- HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy. *J Virol.* 2011; 85:1067–1076. [PubMed: 21084490]
- Klatt NR, Canary LA, Vanderford TH, Vinton CL, Engram JC, Dunham RM, Cronise HE, Swerczek JM, Lafont BA, Picker LJ, Silvestri G, Brenchley JM. Dynamics of SIVmac239 infection in pigtail macaques. *J Virol.* 2011
- Kubo RT, Sette A, Grey HM, Appella E, Sakaguchi K, Zhu NZ, Arnott D, Sherman N, Shabanowitz J, Michel H, et al. Definition of specific peptide motifs for four major HLA-A alleles. *J Immunol.* 1994; 152:3913–3924. [PubMed: 8144960]
- Lafont BA, Buckler-White A, Plishka R, Buckler C, Martin MA. Characterization of pig-tailed macaque classical MHC class I genes: implications for MHC evolution and antigen presentation in macaques. *J Immunol.* 2003; 171:875–885. [PubMed: 12847257]
- Lafont BA, McGraw CM, Stukes SA, Buckler-White A, Plishka RJ, Byrum RA, Hirsch VM, Martin MA. The locus encoding an oligomorphic family of MHC-A alleles (Mane-A*06/Mamu-A*05) is present at high frequency in several macaque species. *Immunogenetics.* 2007; 59:211–223. [PubMed: 17256149]
- Laumoller SL, Holm A, Hilden J, Brunak S, Holst Nissen M, Stryhn A, Ostergaard Pedersen L, Buus S. Quantitative predictions of peptide binding to MHC class I molecules using specificity matrices and anchor-stratified calibrations. *Tissue Antigens.* 2001; 57:405–414. [PubMed: 11556965]
- Liska V, Khimani AH, Hofmann-Lehmann R, Fink AN, Vlasak J, Ruprecht RM. Viremia and AIDS in rhesus macaques after intramuscular inoculation of plasmid DNA encoding full-length SIVmac239. *AIDS Res Hum Retroviruses.* 1999; 15:445–450. [PubMed: 10195754]
- Loffredo JT, Sidney J, Wojewoda C, Dodds E, Reynolds MR, Napoe G, Mothe BR, O'Connor DH, Wilson NA, Watkins DI, Sette A. Identification of seventeen new simian immunodeficiency virus-derived CD8+ T cell epitopes restricted by the high frequency molecule, Mamu-A*02, and potential escape from CTL recognition. *J Immunol.* 2004; 173:5064–5076. [PubMed: 15470050]
- Loffredo JT, Sidney J, Piaskowski S, Szymanski A, Furlott J, Rudersdorf R, Reed J, Peters B, Hickman-Miller HD, Bardet W, Rehrauer WM, O'Connor DH, Wilson NA, Hildebrand WH, Sette A, Watkins DI. The high frequency Indian rhesus macaque MHC class I molecule, Mamu-B*01, does not appear to be involved in CD8+ T lymphocyte responses to SIVmac239. *J Immunol.* 2005; 175:5986–5997. [PubMed: 16237093]
- Loffredo JT, Sidney J, Bean AT, Beal DR, Bardet W, Wahl A, Hawkins OE, Piaskowski S, Wilson NA, Hildebrand WH, Watkins DI, Sette A. Two MHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B*08 and HLA-B*2705, bind peptides with sequence similarity. *J Immunol.* 2009; 182:7763–7775. [PubMed: 19494300]
- Mankowski JL, Queen SE, Fernandez CS, Tarwater PM, Karper JM, Adams RJ, Kent SJ. Natural host genetic resistance to lentiviral CNS disease: a neuroprotective MHC class I allele in SIV-infected macaques. *PLoS One.* 2008; 3:e3603. [PubMed: 18978944]
- Miller MD, Yamamoto H, Hughes AL, Watkins DI, Letvin NL. Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. *J Immunol.* 1991; 147:320–329. [PubMed: 1711081]
- Mothe BR, Sidney J, Dzuris JL, Liebl ME, Fuenger S, Watkins DI, Sette A. Characterization of the peptide-binding specificity of Mamu-B*17 and identification of Mamu-B*17-restricted epitopes derived from simian immunodeficiency virus proteins. *J Immunol.* 2002; 169:210–219. [PubMed: 12077247]
- Peters B, Bui HH, Sidney J, Weng Z, Loffredo JT, Watkins DI, Mothe BR, Sette A. A computational resource for the prediction of peptide binding to Indian rhesus macaque MHC class I molecules. *Vaccine.* 2005
- Peters B, Bui H-H, Frankild S, Nielsen M, Lundegaard C, Kostem E, Basch D, Lamberth K, Harndahl M, Fleri W, Wilson SS, Sidney J, Lund O, Buus S, Sette A. A community resource benchmarking predictions of peptide binding to MHC-I molecules. *PLoS Comput Biol.* 2006; 2:e65. [PubMed: 16789818]
- Pratt BF, O'Connor DH, Lafont BA, Mankowski JL, Fernandez CS, Triastuti R, Brooks AG, Kent SJ, Smith MZ. MHC class I allele frequencies in pigtail macaques of diverse origin. *Immunogenetics.* 2006; 58:995–1001. [PubMed: 17096100]

- Reece JC, Loh L, Alcantara S, Fernandez CS, Stambas J, Sexton A, De Rose R, Petravic J, Davenport MP, Kent SJ. Timing of immune escape linked to success or failure of vaccination. *PLoS ONE*. 2010;5.
- Reed JS, Sidney J, Piaskowski SM, Glidden CE, Leon EJ, Burwitz BJ, Kolar HL, Eernisse CM, Furlott JR, Maness NJ, Walsh AD, Rudersdorf RA, Bardet W, McMurtrey CP, O'Connor DH, Hildebrand WH, Sette A, Watkins DI, Wilson NA. The role of MHC class I allele Mamu-A*07 during SIV(mac)239 infection. *Immunogenetics*. 2011; 63:789–807. [PubMed: 21732180]
- Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. *Cell*. 1993; 74:929–937. [PubMed: 8104103]
- Sadjadpour R, Theodore TS, Igarashi T, Donau OK, Plishka RJ, Buckler-White A, Martin MA. Induction of disease by a molecularly cloned highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimera is multigenic. *J Virol*. 2004; 78:5513–5519. [PubMed: 15113931]
- Sette A, Vitiello A, Reheman B, Fowler P, Nayarsina R, Kast WM, Melief CJ, Oseroff C, Yuan L, Ruppert J, Sidney J, del Guercio MF, Southwood S, Kubo RT, Chesnut RW, Grey HM, Chisari FV. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. *J Immunol*. 1994; 153:5586–5592. [PubMed: 7527444]
- Sette A, Sidney J, Bui HH, Del Guercio MF, Alexander J, Loffredo J, Watkins DI, Mothe BR. Characterization of the peptide-binding specificity of Mamu-A*11 results in the identification of SIV-derived epitopes and interspecies cross-reactivity. *Immunogenetics*. 2005
- Shimizu Y, DeMars R. Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line. *J Immunol*. 1989; 142:3320–3328. [PubMed: 2785140]
- Sidney J, Dzuris JL, Newman MJ, Johnson RP, Kaur A, Amitinder K, Walker CM, Appella E, Mothe B, Watkins DI, Sette A. Definition of the Mamu A*01 peptide binding specificity: application to the identification of wild-type and optimized ligands from simian immunodeficiency virus regulatory proteins. *J Immunol*. 2000; 165:6387–6399. [PubMed: 11086077]
- Sidney J, Southwood S, Oseroff C, del Guercio MF, Sette A, Grey HM. Measurement of MHC/peptide interactions by gel filtration. *Curr Protoc Immunol*. 2001 Chapter 18:Unit 18 3.
- Sidney J, Peters B, Moore C, Pencille TJ, Ngo S, Masterman KA, Asabe S, Pinilla C, Chisari FV, Sette A. Characterization of the peptide-binding specificity of the chimpanzee class I alleles A*0301 and A*0401 using a combinatorial peptide library. *Immunogenetics*. 2007
- Sidney J, Assarsson E, Moore C, Ngo S, Pinilla C, Sette A, Peters B. Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. *Immunome Res*. 2008a; 4:2. [PubMed: 18221540]
- Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. *BMC Immunol*. 2008b; 9:1. [PubMed: 18211710]
- Smith SM, Holland B, Russo C, Dailey PJ, Marx PA, Connor RI. Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV: predictive value for disease progression. *AIDS Res Hum Retroviruses*. 1999; 15:1691–1701. [PubMed: 10606092]
- Smith MZ, Dale CJ, De Rose R, Stratov I, Fernandez CS, Brooks AG, Weinfurter J, Krebs K, Riek C, Watkins DI, O'Connor DH, Kent SJ. Analysis of pigtail macaque major histocompatibility complex class I molecules presenting immunodominant simian immunodeficiency virus epitopes. *J Virol*. 2005; 79:684–695. [PubMed: 15613296]
- Solomon C, Southwood S, Hoof I, Rudersdorf R, Peters B, Sidney J, Pinilla C, Marcondes MC, Ling B, Marx P, Sette A, Mothe BR. The most common Chinese rhesus macaque MHC class I molecule shares peptide binding repertoire with the HLA-B7 supertype. *Immunogenetics*. 2010; 62:451–464. [PubMed: 20480161]
- Southwood S, Solomon C, Hoof I, Rudersdorf R, Sidney J, Peters B, Wahl A, Hawkins O, Hildebrand W, Mothe BR, Sette A. Functional analysis of frequently expressed Chinese rhesus macaque MHC class I molecules Mamu-A1*02601 and Mamu-B*08301 reveals HLA-A2 and HLA-A3 supertypic specificities. *Immunogenetics*. 2011; 63(5):275–290. [PubMed: 21274527]
- Stryhn A, Pedersen LO, Romme T, Holm CB, Holm A, Buus S. Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent

- subspecificities: quantitation by peptide libraries and improved prediction of binding. *Eur J Immunol.* 1996; 26:1911–1918. [PubMed: 8765039]
- Udaka K, Wiesmuller KH, Kienle S, Jung G, Walden P. Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocyte epitopes with complex peptide libraries. *J Exp Med.* 1995; 181:2097–2108. [PubMed: 7539039]
- Udaka K, Wiesmuller KH, Kienle S, Jung G, Tamamura H, Yamagishi H, Okumura K, Walden P, Suto T, Kawasaki T. An automated prediction of MHC class I-binding peptides based on positional scanning with peptide libraries. *Immunogenetics.* 2000; 51:816–828. [PubMed: 10970096]
- Udesi ND, Compton PD, Shabanowitz J, Hunt DF, Rose KL. Methods for analyzing peptides and proteins on a chromatographic timescale by electron-transfer dissociation mass spectrometry. *Nat Protoc.* 2008; 3:1709–1717. [PubMed: 18927556]
- Walsh SR, Gillis J, Peters B, Mothe BR, Sidney J, Sette A, Johnson RP. Diverse recognition of conserved orthopoxvirus CD8+ T cell epitopes in vaccinated rhesus macaques. *Vaccine.* 2009; 27:4990–5000. [PubMed: 19531389]

Fig. 1.

Efficacy of PSCL prediction of Mane-A1*082:01 binders. SHIV peptides were scored using the PSCL matrix. The top 1% scoring peptides were synthesized and tested in competitive binding assays utilizing purified MHC, as previously described (Loffredo et al. 2009; Sidney et al. 2008a; Sidney et al. 2001), and their IC₅₀ (nanomoles) affinities determined. Binders were defined as those with an affinity of 500 nM, or better. **a** Percent binders as a function of the percentile score range; **b** cumulative number of Mane-A1*082:01 binders by percentile score in a complete set of peptides derived from SHIV scoring in the top 4 percentile range by PSCL matrix prediction

Table 1

SAAS-derived matrix describing 9-mer binding to Mane-A1*082:01

Residue	Position								
	1	2	3	4	5	6	7	8	9
A	0.034	0.033	0.371	0.348	0.014	0.368	0.017	0.273	0.006
C	0.169	0.005	0.110	0.448	0.001	0.295	0.143	0.160	0.047
D	0.144	0.005	0.025	0.344	0.005	0.037	0.018	0.161	0.004
E	0.038	0.010	0.013	1.000	0.019	0.131	0.004	0.253	0.001
F	0.206	0.002	0.703	0.586	1.000	0.271	1.000	1.000	1.000
G	0.064	0.002	0.094	0.979	0.031	0.362	0.009	0.132	0.000
H	0.177	1.000	0.330	0.631	0.041	0.110	0.055	0.151	0.006
I	0.207	0.003	0.993	0.041	0.051	0.266	0.040	0.288	0.022
K	0.012	0.001	0.046	0.790	0.018	0.427	0.005	0.149	0.005
L	0.036	0.000	1.000	0.851	0.046	0.024	0.081	0.203	0.089
M	0.264	0.005	0.844	0.729	0.039	0.562	0.060	0.194	0.158
N	0.093	0.000	0.546	0.109	0.033	0.091	0.016	0.025	0.010
P	0.038	0.001	0.020	0.321	0.022	0.590	0.021	0.217	0.001
Q	0.120	0.020	0.318	0.181	0.024	1.000	0.028	0.311	0.001
R	0.070	0.006	0.034	0.253	0.013	0.291	0.016	0.126	0.011
S	0.276	0.000	0.255	0.359	0.008	0.286	0.011	0.171	0.004
T	0.160	0.000	0.233	0.182	0.022	0.238	0.009	0.268	0.006
V	0.324	0.000	0.705	0.089	0.044	0.249	0.013	0.139	0.048
W	1.000	0.000	0.496	0.117	0.061	0.438	0.175	0.799	0.013
Y	0.226	0.000	0.796	0.136	0.105	0.334	0.287	0.388	0.232
Geomean	0.12	0.00	0.21	0.31	0.03	0.24	0.03	0.21	0.01
SD	2.8	7.6	4.2	2.5	4.1	2.5	4.1	2.1	7.8
SF	0.51	24.05	0.28	0.19	2.27	0.25	1.87	0.28	5.26
50-fold	1	17	2	0	7	0	10	0	13

The SAAS panel was tested for binding, the data analyzed, and primary and secondary anchor positions defined, as described in the text. Values shown represent the average relative binding (ARB) of the corresponding single substitution analog peptide relative to other analogs with a substitution at the same position. Values have been normalized to the optimal residue at the corresponding position. SD indicates the standard deviation between the ARB of analogs at the same position. SF is the specificity factor, calculated as described in the text, and represents the ratio of the average binding of the entire

panel to the average of analogs at the indicated position. At the primary anchor positions (SF>5), the most preferred residues, associated with an ARB >0.1 are highlighted by bold font. Fiftyfold indicates the number of substitutions associated with a 50-fold decrease in binding capacity. The panel average binding for Mane-A1*082:01 was 58 nM.

Table 2

Frequency of amino acid residues in eluted peptide ligands and respective positions

Residue	Peptide position														
	1	2	3	4	5	6	7	8	C-term						
A	–	–	0.043	0.087	0.087	0.022	0.043	0.065	–						
C	–	–	–	–	–	–	–	–	–						
D	0.087	–	–	0.087	0.065	0.043	0.022	0.022	–						
E	–	–	0.087	0.130	0.130	0.065	0.109	0.087	0.022						
F	0.022	–	0.065	0.043	0.109	0.022	0.022	0.043	0.152						
G	0.022	0.022	–	0.087	0.022	0.043	–	0.022	–						
H	0.152	0.717	0.065	0.043	0.022	–	0.043	0.087	–						
I	–	–	0.130	0.065	0.087	0.130	0.109	–	–						
K	0.022	0.022	0.065	0.087	0.022	0.130	0.130	0.152	–						
L	0.022	0.022	0.065	0.043	0.109	0.022	0.130	0.087	0.022						
M	0.022	–	0.043	–	–	–	–	0.022	0.130						
N	0.457	–	0.065	0.022	0.065	0.043	0.065	0.043	–						
P	–	–	–	0.087	0.087	0.065	–	–	–						
Q	0.022	0.152	0.130	0.022	0.087	0.109	0.065	–	–						
R	0.022	0.065	0.043	0.022	0.022	0.109	0.022	0.109	–						
S	0.043	–	0.087	0.065	0.043	0.022	–	0.109	–						
T	0.022	–	–	0.022	0.022	–	0.022	0.043	–						
V	0.065	–	0.065	0.043	–	0.087	0.130	0.065	–						
W	–	–	–	0.022	0.022	0.043	–	–	–						
Y	0.022	–	0.043	0.022	–	0.043	0.087	0.043	0.674						
Median	0.022	–	0.054	0.043	0.033	0.043	0.033	0.043	–						
Deleterious	6	14	6	2	4	4	6	5	15						

Values represent the fraction of peptides containing the corresponding residue at the specified position. Deleterious indicates the number of residues never seen in any of the eluted ligands at the indicated position. Peptide ligands endogenously bound to Mane-A1*082:01 molecules purified from single allele transfected 721.221 cells were eluted by acid-boil, then analyzed by reverse-phase nanoflow-HPLC/microelectrospray ionization eluted directly into a Thermo Fisher Scientific Orbitrap Velos mass spectrometer equipped with a commercial ETD source as described previously (Udeshi et al. 2008). The instrument was operated in a data-dependent mode where a full-scan mass spectrum was acquired with the high-resolution mass analyzer and this was then followed by sequential acquisition of CAD and ETD MS/MS. Data from MS/MS experiments were searched against the SwissProt human database using the Open Mass Spectrometry Search Algorithm (OMSSA) software to generate a list of candidate peptide sequences. Select database assignments were confirmed by manual interpretation of the corresponding MS/MS spectra

Table 3

PSCL scoring matrix for prediction of Mane-A1*082:01 binding peptides

Residue	Position								
	1	2	3	4	5	6	7	8	9
A	-0.29	-0.09	0.02	-0.03	0.09	0.09	0.22	0.20	-0.04
C	0.25	-0.03	-0.26	0.13	0.00	-0.03	-0.06	-0.26	-0.38
D	-0.01	-0.54	-0.03	0.09	-0.12	-0.05	-0.15	-0.21	-0.32
E	-0.23	-0.65	-0.59	-0.30	-0.31	-0.04	-0.21	-0.18	-0.58
F	-0.08	0.03	0.34	0.04	0.14	0.25	-0.12	0.30	1.52
G	-0.08	-0.18	-0.11	-0.13	-0.03	-0.19	-0.17	0.04	-0.23
H	0.79	0.56	0.12	-0.05	-0.17	0.16	0.07	-0.13	-0.26
I	0.03	0.15	0.22	-0.19	0.00	0.18	0.21	0.15	0.48
K	-0.23	-0.27	-0.15	-0.34	-0.32	-0.15	-0.50	-0.02	-0.79
L	-0.23	0.21	0.10	-0.09	0.19	0.17	0.18	0.20	0.67
M	0.15	0.43	0.27	-0.03	0.16	-0.40	0.19	0.11	1.03
N	0.38	-0.03	0.07	0.05	-0.05	-0.10	0.09	-0.14	-0.33
P	-0.32	0.20	-0.02	0.11	-0.08	-0.07	0.09	-0.24	-0.93
Q	-0.04	0.52	0.04	-0.01	-0.22	0.07	0.06	0.05	-0.72
R	-0.07	0.38	-0.20	0.09	-0.28	-0.10	-0.19	-0.01	-0.86
S	0.00	0.09	0.10	0.23	0.29	0.03	0.10	-0.02	-0.53
T	-0.06	-0.32	-0.02	0.06	-0.14	-0.04	0.13	0.11	-0.36
V	-0.09	-0.07	0.08	0.15	0.25	0.10	0.10	0.14	0.39
W	0.07	-0.25	0.04	0.13	0.43	0.07	-0.12	-0.32	0.27
Y	0.06	-0.14	-0.02	0.10	0.19	0.03	0.09	0.23	1.97

Values represent the log of the normalized ARB value for the corresponding PSCL mixture. The prediction score for a peptide represents the sum of the log values of the corresponding amino acid residue at each position. Each SHIV peptide was scored and then ranked against all other SHIV peptides of the same size. For the SHIV 9-mers, the top 1% is equivalent to a score of 2.2. By comparison, in a set of over 58,000 9-mers derived from vaccinia, the 1% threshold corresponded to a score of 2.52